Barclays Initiates Coverage On Edwards Lifesciences with Overweight Rating, Announces Price Target of $110

Benzinga Newsdesk www.benzinga.com Neutral 60.7%

Neg 0% Neu 60.7% Pos 0%

Barclays analyst Christopher Pasquale initiates coverage on Edwards Lifesciences (NYSE:EW) with a Overweight rating and announces Price Target of $110.